lyellbiotech.comHealthcareFounded: 2018Funding to Date: $358MM
Lyell Immunopharma is a developer of curative cell-based immunotherapies for any cancer, with a focus on CAR-Ts and solid tumors.
For more details on financing and valuation for Lyell, register or login.
By registering, you agree to Forge’s Terms of Use. Already registered? Log in
View Enterprise Value for Lyell.
To read this article and more news on Lyell, register or login.